The MHN2-25 monoclonal antibody specifically binds to an extracellular domain of human Notch2. Notch2 is a type 1 transmembrane glycoprotein receptor and member of the Notch family that includes Notch1-Notch4. Notch2 is cleaved in the Golgi and presents as a cell surface heterodimeric receptor. The Notch2 receptor can bind to several membrane-bound ligands including Jagged1, Jagged2, Delta1 and Delta4. Upon ligand binding, Notch2 undergoes proteolytic cleavage that results in the release of the Notch intracellular domain, NICD. NICD translocates to the nucleus where it forms a transcriptional activator complex with various transcriptional factors. These multimeric complexes either positively or negatively regulate the expression of multiple genes including those that orchestrate many facets of embryonic development and the subsequent functioning of multiple organ systems such as the hematopoietic, immune, cardiovascular, hepatic and renal systems. Notch2 is expressed by cells of the lung and brain, as well as cells of the B lineage, thymocytes, and T cells. Abnormalities in Notch2 expression may play a role in the development of B cell lymphomas.
The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.